INO

Company Overview — What Does INOVIO PHARMACEUTICALS, INC. Do?

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. INOVIO PHARMACEUTICALS, INC. (INO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Jacqueline E. Shea and employs approximately 320 people, headquartered in SAN DIEGO, Pennsylvania. With a market capitalization of $120M, INO is one of the notable companies in the Healthcare sector.

INOVIO PHARMACEUTICALS, INC. (INO) Stock Rating — Avoid (April 2026)

As of April 2026, INOVIO PHARMACEUTICALS, INC. receives a Avoid rating with a composite score of 24.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.INO ranks #4,175 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, INOVIO PHARMACEUTICALS, INC. ranks #742 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INO Stock Price and 52-Week Range

INOVIO PHARMACEUTICALS, INC. (INO) currently trades at $1.06. The stock gained $0.01 (1.0%) in the most recent trading session. The 52-week high for INO is $2.98, which means the stock is currently trading -64.4% from its annual peak. The 52-week low is $1.30, putting the stock -18.5% above its annual trough. Recent trading volume was 2.5M shares, reflecting moderate market activity.

Is INO Overvalued or Undervalued? — Valuation Analysis

INOVIO PHARMACEUTICALS, INC. (INO) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.56x, versus the sector average of 2.75x. The price-to-sales ratio is 1311.11x, compared to 1.66x for the average Healthcare stock.

At current multiples, INOVIO PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

INOVIO PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

INOVIO PHARMACEUTICALS, INC. (INO) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -472.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -153.2% versus the sector average of -33.1%.

The operating margin is -38337.0% (sector: -66.1%). Net profit margin stands at -30140.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INO Debt, Balance Sheet, and Financial Health

INOVIO PHARMACEUTICALS, INC. has a debt-to-equity ratio of 208.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.40x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $37M.

INO has a beta of 0.94, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for INOVIO PHARMACEUTICALS, INC. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

INOVIO PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, INOVIO PHARMACEUTICALS, INC. reported revenue of $65,343 and earnings per share (EPS) of $-1.81. Net income for the quarter was $-114M. Gross margin was 0.0%. Operating income came in at $-97M.

In FY 2025, INOVIO PHARMACEUTICALS, INC. reported revenue of $65,343 and earnings per share (EPS) of $-1.81. Net income for the quarter was $-85M. Revenue grew -70.0% year-over-year compared to FY 2024. Operating income came in at $-87M.

In Q3 2025, INOVIO PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.87. Net income for the quarter was $-45M. Operating income came in at $-21M.

In Q2 2025, INOVIO PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.61. Net income for the quarter was $-24M. Operating income came in at $-23M.

Over the past 8 quarters, INOVIO PHARMACEUTICALS, INC. has experienced revenue contraction from $100,762 to $65,343. Investors analyzing INO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INO Dividend Yield and Income Analysis

INOVIO PHARMACEUTICALS, INC. (INO) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INO Momentum and Technical Analysis Profile

INOVIO PHARMACEUTICALS, INC. (INO) has a momentum factor score of 23/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

INO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, INOVIO PHARMACEUTICALS, INC. (INO) ranks #742 out of 838 stocks based on the Blank Capital composite score. This places INO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INO vs S&P 500 (SPY) comparison to assess how INOVIO PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

INO Next Earnings Date

No upcoming earnings date has been announced for INOVIO PHARMACEUTICALS, INC. (INO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INO? — Investment Thesis Summary

The quantitative profile for INOVIO PHARMACEUTICALS, INC. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 23/100, a headwind for near-term performance. High volatility (stability score 28/100) increases portfolio risk.

In summary, INOVIO PHARMACEUTICALS, INC. (INO) earns a Avoid rating with a composite score of 24.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INO stock.

Related Resources for INO Investors

Explore more research and tools: INO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INO head-to-head with peers: INO vs AZN, INO vs SLGL, INO vs VMD.